Accredo’s experience with enzyme replacement therapies began when we dispensed and shipped the first commercial Ceredase prescription in 1991. We currently dispense all the therapies as indicated for the following lysosomal storage disorders:

• Fabry Disease
• Gaucher Disease - Type 1
• Hunter Syndrome (MPS II)
• Hurler-Scheie (MPSI)
• MPS IV
• Pompe Disease